In the last 10 years, APAC has become a hotspot for clinical trials: the region contributed almost 50% of new clinical trial activity globally in 2021.

​

It is often said that “disease knows no borders,” but is the same true for clinical development? Patient availability is a critical component for clinical trials, and so it stands to reason that clinical development should match the epidemiology of diseases. Of course, this is often not the case, with longstanding biases towards studies in the US and Europe, where health care infrastructure and the pharmaceutical market are generally more mature. However, change is underway.

According to GlobalData, of the trials planned for 2022 (data as of 15 May 2022) APAC region has the bulk of the clinical trials with 54%, followed by North America and Europe at 27% and 20%, respectively. As per the information available in GlobalData’s Pharma Intelligence Center’s Clinical Trials Database, there are 2,430 trials planned for 2022 in APAC as of 15 May 2022.

ClinActis has been a leading CRO in Asia since 2009, providing high-quality international clinical research expertise to our clients. With our global trial experience and local knowledge, we bring a unique perspective and expertise to the region, standing out as a trusted provider of international clinical trial quality standards in Asia Pacific.